Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong.

Herbert Ho-Fung LoongCarlos K H WongLinda K S LeungS C TanJason JenMary Y K LeeRaquel Aguiar-IbáñezJingshu Wang

Published in: Cost effectiveness and resource allocation : C/E (2020)

Pembrolizumab is cost-effective relative to chemotherapy (DTIC, TMZ and PC), and highly-cost-effective compared to ipilimumab, for the first-line treatment of advanced melanoma in Hong Kong.

Keyphrases

advanced non small cell lung cancer
healthcare
skin cancer
palliative care
locally advanced
basal cell carcinoma
pain management
squamous cell carcinoma
radiation therapy